Trading for a Living
TBA.
正文
*One Stock Before the Bell*
*Charles River Laboratories International Inc (NYSE: CRL)*
$219.84 (-0.11% YTD)
Charles River provides early-stage *contract research organization (CRO) services* for pharmaceuticals and other institutions. CROs *conduct research and clinical trials for firms trying to get new drugs FDA-approved and gain entry into the market*. Clients typically hire CRL for the entire drug approval process, potentially *locking clients in for over 10 years* until final FDA approval. This provides the company with earnings stability in the event of a downturn.
CRL has *beaten EPS estimates in 12 consecutive quarters*. *Q3 Revenue* grew by 10.40% YoY. The stock looks undervalued at a *blended forward P/E ratio of 19.0x*, a *23% discount* to peers and a *19% discount* to its 5Y average P/E. The CRO market remains attractive with *big pharma increasing their outsourcing of R&D* as internal efforts are typically unproductive.
*Charles River Laboratories International Inc (NYSE: CRL)*
$219.84 (-0.11% YTD)
Charles River provides early-stage *contract research organization (CRO) services* for pharmaceuticals and other institutions. CROs *conduct research and clinical trials for firms trying to get new drugs FDA-approved and gain entry into the market*. Clients typically hire CRL for the entire drug approval process, potentially *locking clients in for over 10 years* until final FDA approval. This provides the company with earnings stability in the event of a downturn.
CRL has *beaten EPS estimates in 12 consecutive quarters*. *Q3 Revenue* grew by 10.40% YoY. The stock looks undervalued at a *blended forward P/E ratio of 19.0x*, a *23% discount* to peers and a *19% discount* to its 5Y average P/E. The CRO market remains attractive with *big pharma increasing their outsourcing of R&D* as internal efforts are typically unproductive.
評論
目前還沒有任何評論
登錄後才可評論.
